401 Background: To validate the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with the tyrosine kinase ...

Temsirolimus in Poor-Risk mRCC Patients In treatment-naive patients, four regimens have been approved based on level 1 evidence from randomized controlled trials: sunitinib, bevacizumab/IFN-α ...

Julia Choy, MD, of Barts Cancer Institute in London, UK, and colleagues identified 112 patients with mRCC who underwent a deferred CN at a median 111.5 days following treatment with the targeted ...

397 Background: During the last ten years, several classifications have been used to assess the prognosis in mRCC. In none of them, tumor burden (TB) has been considered. This study investigates the ...

Cytoreductive nephrectomy (CN) in conjunction with immune checkpoint inhibitor (ICI) therapy for metastatic renal cell carcinoma (mRCC) is associated with significantly longer overall survival ...